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Abstract 
Recent studies have shown that murine cardiomyocytes possess a functional intrinsic 
cholinergic system that can synthesize and release acetylcholine (ACh). The way by 
which ACh release is regulated however, is not fully understood. Classically, ACh 
released from neuronal sources is regulated by the vesicular ACh transporter (VAChT). 
We tested the hypothesis that ACh released from neonatal murine cardiomyocytes is 
regulated via the VAChT by pharmacologically inhibiting or genetically removing this 
transporter selectively from cardiomyocytes. Pharmacological inhibition of the VAChT 
using vesamicol (VES) revealed a significant reduction in ACh release from cultured 
cardiomyocytes. Cardiomyocytes from genetically-modified mice where the VAChT was 
selectively removed revealed similar reductions in ACh release. Similar to its role within 
nerve terminals, these data suggest that the VAChT serves an essential role in regulating 
ACh release from cardiomyocytes. These experiments suggest that non-neuronal ACh 
released from cardiomyocytes may act to amplify the effects of neuronally released ACh. 
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Chapter 1  
1 Introduction  
1.1 Cholinergic Neurotransmission 
Neurotransmitters are those chemicals endogenous to an organism which act by 
transmitting impulses across synaptic clefts located either between pre- and post-synaptic 
neurons or pre-synaptic neurons and  target cells (Purves D, 2001). Acetylcholine (ACh), 
one of the most widely studied neurotransmitters to date, was discovered in 1926 by the 
German physiologist, Otto Loewi. The discovery came following the dissection of two 
beating frog hearts; one with an intact vagus nerve and the other lacking it. Loewi then 
placed both hearts into a saline solution, stimulated the vagus nerve of the intact heart, 
and the result was a decrease in heart rate (HR). Loewi then took a portion of the fluid 
from the stimulated heart and applied it to the second heart where he found a similar 
reduction in HR. This led Loewi to conclude that HR was being regulated by a chemical 
released from the vagus nerve (Purves D, 2001). The molecule that would eventually be 
given the name ACh, serves as a neurotransmitter for both the central (CNS) and 
peripheral nervous systems (PNS).  
In order for ACh to function as a neurotransmitter, it must be synthesized, packaged into 
vesicles, released into the synaptic cleft, and finally degraded by an acetylcholinesterase 
enzyme (AChE). These processes are tightly regulated through three main cholinergic 
proteins including the high affinity choline transporter (CHT1), the choline 
acetyltransferase (ChAT) enzyme, and the vesicular acetylcholine transporter (VAChT). 
Choline, a water soluble essential nutrient required for sustaining life, serves a role in 
brain development, cellular membrane structure, and the modulation of several cell 
signaling processes (Zeisel & Blusztajn, 1994). The uptake of choline from extracellular 
sources, for the purposes of cholinergic signaling, is under the regulation of the high 
affinity choline transporter, CHT1 (Collier & Katz, 1974; R. Birks, 1961). This protein is 
a 63 kDa protein which belongs to the Na+-dependent glucose transporter family, SLC5 
(SLC5A7) (Apparsundaram, Ferguson, George, & Blakely, 2000; Okuda et al., 2000). As 
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the name implies, CHT1 is a membrane embedded protein that exhibits high affinity for 
choline molecules present within extracellular spaces (Brandon et al., 2004; Collier & 
Katz, 1974; R. Birks, 1961). The high affinity choline transporter localizes mainly at the 
membrane of synaptic vesicles, but has also been found, albeit at lower levels, at the 
membrane of pre-synaptic nerve endings (Ferguson et al., 2003; Ribeiro et al., 2003). The 
high affinity choline transporter has often been described as the rate-limiting step in the 
synthesis of ACh considering that the specific inhibition of CHT1 by hemicholinium-3 
(HEM) results in severe deficits in cholinergic function (R. Birks, 1961; Ribeiro et al., 
2003). However, under circumstances in which there is a period of prolonged neuronal 
stimulation, the synthesis and release of ACh is sustained as long as CHT1 is functioning 
properly and as long as there is sufficient choline available for uptake (Ribeiro et al., 
2006). Considering CHT1 localizes predominately at the membrane of synaptic vesicles, 
prolonged neuronal stimulation not only increases synaptic vesicle exocytosis, but it 
increases the amount of CHT1 present at the plasma membrane following exocytosis. 
These conditions facilitate an increase in choline re-uptake by the pre-synaptic neuron 
which mediates increased ACh synthesis and provides the foundation  required to sustain 
prolonged neuronal stimulation (Ribeiro et al., 2006). 
Choline acetyltransferase, an enzyme often attributed as being the phenotypical marker of 
cholinergic neurons, is a ~69 KD (Dobransky & Rylett, 2003), monomeric, globular 
protein (Oda, 1999) responsible for synthesizing ACh from the precursors, choline and 
acetyl-CoA (Dobransky & Rylett, 2003). Acetyl-CoA, a biologically important molecule 
used in several biochemical reactions, is obtained through three main endogenous 
reactions. These reactions include glycolysis, the degradation of amino acids, and the 
oxidation of fatty acids (Oda, 1999). Although ChAT is located all throughout 
cholinergic neurons, its highest concentration exists within the nerve terminals (Oda, 
1999). Choline acetyltransferase is initially produced within the cell body of cholinergic 
neurons before being transported to the nerve terminal through axoplasmic transport 
(Dziegielewska et al., 1976; Frizell, Hasselgren, & Sjostrand, 1970). Synthesis of ACh by 
ChAT commences in the cytoplasm of nerve terminals (Govindasamy et al., 2004; Oda, 
1999; Parsons, 2000; M. A. Prado et al., 2002; V. F. Prado, Roy, Kolisnyk, Gros, & 
Prado, 2013). Synthesis occurs through a single step reaction in which an acetyl group 
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from acetyl-CoA is transferred to a single molecule of choline (Govindasamy et al., 2004; 
Oda, 1999; Yamada, Imajoh-Ohmi, & Haga, 2012). It has also been shown that the open 
reading frame of the VAChT, another important protein used in cholinergic signaling, lies 
within the first intron of the ChAT gene (Alfonso, Grundahl, McManus, Asbury, & Rand, 
1994; Bejanin, Cervini, Mallet, & Berrard, 1994). This may be of particular importance 
as it could suggest that the expression of ChAT and the VAChT are coregulated within 
cholinergic neurons. 
The VAChT is a ~75 kDA protein  (Alfonso, Grundahl, Duerr, Han, & Rand, 1993; 
Roghani et al., 1994; Varoqui & Erickson, 1996) responsible for loading ACh 
synthesized by ChAT into acidic secretory vesicles (Parsons, Prior, & Marshall, 1993; 
Usdin, Eiden, Bonner, & Erickson, 1995). The VAChT, a member of the solute carrier 
family, SLC18, is a protein found in both neuronal cell bodies, as well as the nerve 
terminals of cells containing the ChAT protein (Roghani, Shirzadi, Butcher, & Edwards, 
1998; Schafer, Eiden, & Weihe, 1998). The VAChT consists of 12 transmembrane 
spanning domains which orient themselves into two main bundles such that the amino-
terminus and carboxyl-terminus are both directed towards the cytosolic side of the cell 
(V. F. Prado et al., 2013). The two main bundles undergo a back and forth-like motion 
such that the substrate-binding site is exposed to either the cytoplasm of the cell or the 
interior of the synaptic vesicle (Nguyen, Cox, & Parsons, 1998). This motion allows ACh 
to be packaged into acidic vesicles through the exchange of two luminal protons per 
cytoplasmic molecule of ACh (Nguyen et al., 1998). 
The VAChT mediated storage of ACh can be pharmacologically inhibited through the 
use of vesamicol [(−)-trans-2-(4-phenylpiperidino) cyclohexanol] (VES) (V. F. Prado et 
al., 2013; Prior, Marshall, & Parsons, 1992). Vesamicol is a tertiary amine that can 
traverse the cell membrane and bind to the VAChT such that it inhibits the transport of 
ACh (Nguyen et al., 1998; Parsons et al., 1993). Inhibition by VES has been shown to be 
non-competitive in nature indicating that its inhibitory actions take place at a site external 
to the ACh binding site (Bahr, Clarkson, Rogers, Noremberg, & Parsons, 1992). 
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1.2 Nicotinic and Muscarinic ACh Receptors 
Nicotinic ACh receptors (nAChRs), a class of integral membrane proteins, are receptors 
which serve as ligand gated ion channels within cholinergic neurotransmission (Chesher 
& James, 1966; Kalamida et al., 2007). Nicotinic ACh receptors are composed of 5 
transmembrane subunits organized around a central pore and can vary in function 
depending on the polypeptide subunits that are present (α1-10, β1-4, γ, δ, and ε) 
(Lindstrom, 1997). Although all nAChRs are composed of 5 transmembrane subunits 
organized around a central pore, these receptors can be further divided into neuronal and 
muscular subtypes (Marshall, 1981). Neuronal subtypes are those receptors that associate 
with the CNS, the PNS, and non-neuronal ACh sources (Kalamida et al., 2007). In 
contrast, muscular subtypes, as the name implies, are those receptors that associate with 
the neuromuscular junction and act to mediate muscular contraction (Kalamida et al., 
2007). Although nAChRs serve an important role within cholinergic neurotransmission, 
particular focus will be placed on the role muscarinic acetylcholine receptors (mAChRs) 
serve in such transmission. 
Muscarinic acetylcholine receptors, a class of G-protein coupled receptors (GPCRs), are 
membrane embedded proteins that are present within various cells types, including 
neurons, and are responsible for mediating several diverse functions within an organism 
(Ashkenazi, Peralta, Winslow, Ramachandran, & Capon, 1988). Named as such because 
of their increased sensitivity to muscarine, five different mAChR subtypes have been 
identified (M1-M5) (Bonner, Young, Brann, & Buckley, 1988; Hulme, Birdsall, & 
Buckley, 1990; Kubo et al., 1986; Liao et al., 1989). All muscarinic receptor subtypes are 
composed of seven transmembrane spanning domains with a carboxyl-terminus directed 
intracellularly and an amino-terminus directed extracellularly (Dhein, van Koppen, & 
Brodde, 2001). The ligand binding site of these receptors are situated within the outer 
half of the membrane embedded portion of the receptor protein (Dhein et al., 2001). 
Ligand binding and subsequent activation of the various receptor subtypes can produce 
differing responses depending on the G-protein the receptor subtype is coupled to (Dhein 
et al., 2001). Odd numbered muscarinic receptor subtypes (M1, M3, and M5) for 
instance, are coupled to Gq/11 G-proteins, which when activated, results in phospholipase 
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C (PLC) stimulation (Dhein et al., 2001; Ishii & Kurachi, 2006). Activation of PLC 
initiates a cascade of events beginning with the hydrolysis of Phosphatidylinositol 4,5-
bisphosphate (PIP2) to its constituents, diacyl glycerol (DAG) and inositol triphosphate 
(IP3) (Dhein et al., 2001; Ishii & Kurachi, 2006). Following PIP2 hydrolysis, DAG acts as 
a second messenger to activate Protein Kinase C, while IP3 acts to increase intracellular 
calcium levels (Dhein et al., 2001; Ishii & Kurachi, 2006).  In contrast, even numbered 
receptor subtypes (M2 and M4) are coupled to Gi/o G-proteins, which when activated, 
serve to inhibit adenylyl cyclase activity (Nathanson, 1987). Consequently there is 
decreased production of cyclic adenosine monophosphate (cAMP) and a subsequent 
decrease in Protein Kinase A (PKA) activity (Dhein et al., 2001; Ishii & Kurachi, 2006). 
Gi/o G-proteins also mediate the activation of G protein-gated potassium channels 
resulting in the hyperpolarization of excitable cells (Kim et al., 1989; Logothetis, 
Kurachi, Galper, Neer, & Clapham, 1987; Yatani et al., 1988).  
There are five different mAChR subtypes which exist and a particular tissue is capable of 
expressing multiple receptor subtypes at any given time (Brodde & Michel, 1999). For 
instance, the heart expresses, albeit at different levels, both M2 and M3 receptor subtypes 
(Sharma, Colecraft, Rubin, & Sheu, 1997; Z. Wang, Shi, & Wang, 2004; Yang, Yeh, 
Sung, Chen, & Wang, 1992). The M2 receptor subtype, denoted as the muscarinic type-2 
ACh receptor (mAChR-2), is the predominant receptor subtype present within the heart. 
The M3 receptor subtype seems to serve only a minor role as it has been described as 
carrying-out functions associated mainly with the coronary circulation (Dhein et al., 
2001). For this reason, the mAChR-2 and the effects it exerts on the heart are of 
particular importance.  
Muscarinic type-2 ACh receptors can be activated by a plethora of different agonists 
including ACh and carbachol (Carb) (Brodde & Michel, 1999). When these receptors are 
activated at the heart, a reduction in heart rate (chronotropy), force of contraction 
(inotropy), and conduction velocity (dromotropy) ensues (Brodde & Michel, 1999). More 
specifically, activation of these receptors at the sinoatrial node (SA) elicits an increase in 
outward potassium conductance, while decreasing the inward conductance of calcium 
and sodium ions. Consequently, SA nodal cells hyperpolarize and reduce the rate at 
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which these cells spontaneously depolarize. The net result is a reduction in the rate of 
action potential (AP) firing from these cells (Giessler, Dhein, Ponicke, & Brodde, 1999). 
Furthermore, activation of mAChRs-2 produces a shortened AP within the atria, as well 
as a decrease in the velocity at which the AP propagates through the atrioventricular 
(AV) node (Giessler et al., 1999). Lastly, activation of these receptors can elicit a slight 
reduction in the force at which the ventricles contract, as long as the cAMP pathway has 
been stimulated beforehand in a phenomenon termed accentuated antagonism (Brodde & 
Michel, 1999; Giessler et al., 1999; Levy, 1984). The effects produced by mAChR-2 
activation can be competitively inhibited through the use of atropine (ATR), a non-
specific muscarinic receptor antagonist (Bhattacharjee, Pomponio, Evans, Pervitsky, & 
Gordon, 2013).  
 
1.3 The Role of Acetylcholinesterase in Cholinergic 
Neurotransmission 
Acetylcholinesterase, a hydrolase enzyme located within the synaptic cleft of cholinergic 
neurons, serves to hydrolyze ACh into acetic acid and choline (Sussman et al., 1991; 
Pohanka, 2011). The enzymatic breakdown of ACh is a crucial process required by 
organisms to maintain cholinergic neurotransmission. The active site of these enzymes is 
composed of two subsites including the anionic subsite, as well as the esteratic subsite 
(Sussman et al., 1991). The anionic subsite is responsible for interacting with the 
quarentary amine of the ACh molecule to ensure the molecule is in the correct 
orientation for subsequent hydrolysis (Sussman et al., 1991).  The esteratic subsite 
however, is the portion of the active site where the ester bond joining acetic acid and 
choline together is broken through hydrolysis. This site contains three essential amino 
acids including serine, histidine, and glutamate and is often referred to as the catalytic 
triad (Silman & Sussman, 2008; Sussman et al., 1991). The hydrolysis of ACh by 
AChEs to acetic acid and choline can be slowed however, through the use of 
acetylcholinesterase inhibitors (AChEIs). The method by which AChEIs exerts their 
inhibitory effects depends on the type of AChEI present. The two AChEIs of particular 
importance, pyridostigmine (PYR) and neostigmine (NEO), act as reversible inhibitors 
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to the AChE enzyme (Androne, Hryniewicz, Goldsmith, Arwady, & Katz, 2003; Miller, 
Van Nyhuis, Eger, Vitez, & Way, 1974). Although both inhibitors act in a similar 
fashion, PYR, compared to NEO, requires more time to reach peak onset, but its actions 
as a cholinesterase inhibitor are of a longer duration (Miller et al., 1974; Smith, Mead, & 
Unna, 1957).   
 
1.4 An Overview of Cholinergic Neurotransmission 
After discussing the roles of CHT1, ChAT, the VAChT, nAChRs, mAChRs, AChEs and 
AChEIs in cholinergic neurotransmission, a broader picture depicting how cholinergic 
neurotransmission proceeds can be put forth. The initial stage of cholinergic 
neurotransmission begins in the cytoplasm of the nerve terminal where ACh is 
synthesized through the enzymatic actions of ChAT (Dobransky & Rylett, 2003). 
Following its synthesis,  ACh is then packaged into acidic vesicles through the actions of 
the VAChT (V. F. Prado et al., 2013). Once ACh is packaged into acidic vesicles, ACh is 
ready for release into the synaptic cleft where it can bind to nAChRs or mAChRs to elicit 
a given response. In order for the vesicular contents to be released into the synaptic cleft 
in a synchronous fashion however, an AP must first be generated at the cell body of the 
neuron. Following its generation, the AP then propagates to the nerve terminal (Hall, 
2010; Katz, 1969). Depolarization of the nerve terminal results in the opening of voltage-
gated calcium channels causing an influx of extracellular calcium into the pre-synaptic 
neuron (Katz, 1969). Calcium influx in turn causes ACh-containing vesicles to fuse with 
the membrane of the pre-synaptic neuron at which point ACh is released into the synaptic 
cleft through a process known as exocytosis (Hall, 2010; Katz, 1969). Depending on the 
location of the synapse, ACh released into the synaptic cleft is free to act on either 
nAChRs (Guo, Liu, Sorenson, & Chiappinelli, 2005) or mAChRs (Abramochkin et al., 
2010). These effects are short lived however, because of the actions of the AChE 
enzyme. These enzymes work at an extremely rapid rate to hydrolyze ACh to acetic acid 
and choline (Minic, Molgo, Karlsson, & Krejci, 2002; Soreq & Seidman, 2001). 
Following the enzymatic breakdown of ACh, choline can be recycled back into the nerve 
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terminal through the actions of CHT1 (Collier & Katz, 1974; R. Birks, 1961) where it can 
then be utilized for the synthesis of additional molecules of ACh. 
 
1.5 Neural and Humoral Control of the Heart 
The pumping and subsequent delivery of blood through the use of a connected circulatory 
system is critical for the delivery of oxygen and essential nutrients to each and every cell 
of the body (Vadakkumpadan et al., 2010). The delivery of blood can be altered however, 
in order to meet the metabolic demands of the body by altering vascular resistance or by 
altering the heart’s inotropic and chronotropic responses. The frequency and strength at 
which these contractions occur is regulated by both a system intrinsic to the heart, as well 
as system extrinsic to the heart (Randall, Evans, Billman, Ordway, & Knapp, 1981).  
Intrinsic control of the heart refers to the hearts’ ability to regulate its inotropic and 
chronotropic responses in the absence of external neural control. Intrinsic control of the 
heart is regulated by a specialized group of cells often referred to as pacemaker cells 
(Tessadori et al., 2012).  Pacemaker cells are responsible for initiating and distributing 
electrical impulses in a coordinated fashion throughout the heart (Tessadori et al., 2012). 
In other words, the heart can be described as having automaticity or self-excitability, 
since cardiomyocytes are capable of initiating spontaneous electrical impulses in the 
absence of external neural control. The spontaneous depolarization of pacemaker cells is 
the result of changes in membrane conductance to sodium, potassium, and calcium ions 
(Jones Bernardes Graceli, 2012). Once pacemaker cells reach threshold, an impulse is 
generated where it then propagates through internodal pathways (Kafer, 1991). 
Propagation through these pathways allows for atrial depolarization followed by atrial 
contraction (Kafer, 1991). During atrial contraction, the impulse propagates to a 
specialized group of cells located within the atrial septum known as the AV node (Chi et 
al., 2008). While the AV node depolarizes, repolarization of both the SA node and the 
internodal pathways commences (Nada et al., 2013). Following a slight delay at the AV 
node to allow for ventricular filling (Chi et al., 2008; Marger et al., 2011), the impulse 
then propagates through the bundle of His, as well as the left and right bundle branches, 
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before finally reaching the Purkinje fibers (Chi et al., 2008). Depolarization of the 
Purkinje fibers causes ventricular contraction from the apex of the heart to the base of the 
heart resulting in the expulsion of blood from the ventricles (Chi et al., 2008).  During 
ventricular contraction, the atria rest and undergo repolarization (Nada et al., 2013). 
Following ventricular contraction, the AV node, the bundle of His, and the Purkinje 
fibers repolarize while the ventricles relax (Nada et al., 2013). In some cases however, 
the pacemaker cells of the SA node lose their automaticity. Considering that other cells in 
the heart are self-excitable, the role of the pacemaker can be assumed by these cells, 
albeit at a slower rate. The first area of the heart to embrace this role once pacemaker 
cells lose their automaticity, are the cells of the AV node (Marger et al., 2011). If for 
some reason the cells of the AV node also lose their automaticity, the role can be 
assumed by the bundle of His and the Purkinje fibers (Chay & Lee, 1984). Under normal 
circumstances, the self-excitability of the AV node, the bundle of His, and the Purkinje 
fibers are much slower than the pacemaker cells of the SA node (Tessadori et al., 2012). 
Consequently, APs generated by the SA node are able to propagate through the 
conduction system and excite the AV node, the bundle branches, and the Purkinje fibers 
before these areas have a chance to generate their own spontaneous AP (Tessadori et al., 
2012). For this reason, the spontaneous generation of APs by the SA node tends to be 
approximately 100 times per minute but because of extrinsic regulation, this rate is 
modified to approximately 70 times per minute.  
Extrinsic control of the heart refers to the organism’s ability to externally regulate heart 
function through the release of neurotransmitters [ie. Norepinephrine (NE) and ACh] 
from the autonomic nervous system (ANS) (Vaseghi & Shivkumar, 2008). The ANS, a 
division of the PNS, is responsible for controlling involuntary and visceral functions 
(Chen, Wasmund, & Hamdan, 2006). At the heart specifically, the ANS is responsible for 
regulating the hearts’ chronotropic, inotropic, and dromotropic effects through the 
coordinated interplay of its two subdivisions (Vaseghi & Shivkumar, 2008) which 
include the sympathetic (SNS) and parasympathetic nervous systems (PSNS).  
The SNS is a division of the PNS often referred to as the “fight-or-flight” system and its 
actions predominate over the PSNS during time of physiological stress (Floras, 2009). 
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With reference to the heart, adrenergic nerves of the SNS originate in the thoracic and 
lumbar regions of the spine before eventually innervating the atria, the ventricles, and the 
ventricular conducting system (Camici, 2002; Chen et al., 2006; Ieda & Fukuda, 2009; 
Mitchell, 1953). During times of physiological stress, an increase in SNS activity causes 
an increase in NE secretion from adrenergic fibers. Consequently, there is an increased 
concentration of circulating NE which can be utilized for the activation of β-adrenergic 
receptors (Camici, 2002; Parati & Esler, 2012). β-adrenergic receptors are a class of 
GPCRs that are activated by catecholamines including epinephrine and NE (Ablad et al., 
1974). Activation of these receptors increases the level of activity in the c-AMP-
dependent pathway (Bristow, Hershberger, Port, Minobe, & Rasmussen, 1989). In short, 
activation of adenylyl cyclase by the Gs alpha subunit of the G-protein complex increases 
cAMP production and ultimately causes an increase in PKA activity (Bristow et al., 
1989). Activation of PKA leads to several downstream effects at the heart including those 
effects aforementioned (Vaseghi & Shivkumar, 2008). 
 The PSNS however, is a division of the PNS often referred to as the “rest-and-digest” 
system and its actions predominate over the SNS during times of rest and relaxation 
(Stewart, Huang, & Fisher, 2012). In contrast to the SNS, the vagus nerve of the PSNS 
originates in the brainstem and innervates the SA/AV nodes, the atria, the ventricular 
conducting system, but only sparsely innervates the ventricles (Blotnick, Hamra-Amitai, 
Wald, Brenner, & Anglister, 2012; Chen et al., 2006; Hildreth, Anderson, & Henderson, 
2009; Mitchell, 1953). Activation of the PSNS elicits an increase in ACh release from 
cholinergic neurons. Consequently, there is an increase in mAChR-2 activation resulting 
in an increased cholinergic tone (Abramochkin et al., 2010; Minic et al., 2002; Wessler & 
Kirkpatrick, 2008). Like β-adrenergic receptors, mAChRs-2, as previously described, are 
a class of GPCRs that regulate chronotropy, inotropy, and dromotropy (Brodde & 
Michel, 1999; Giessler et al., 1999). In contrast to β-adrenergic receptors however, 
mAChRs-2 work to decrease those effects previously mentioned (Brodde & Michel, 
1999; Giessler et al., 1999) It should also be noted that chemical stimuli present within 
the circulation (ie. tissue metabolites, CO2, O2, and adenosine) can effect cardiac function 
by altering the degree of neural outflow from the SNS and the PSNS (Thomas, 2011). 
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1.6 The importance of ACh in Maintaining Cardiovascular 
Homeostasis 
Cholinergic neurotransmission plays an important role in maintaining cardiovascular 
health considering that alterations in cholinergic protein expression and/or a withdrawal 
of PSNS activity elicits several cardiovascular deficits. Although decreased cholinergic 
tone results in deficits including left ventricular dysfunction (Lara et al., 2010), decreased 
HR variability (Serra, Costa, Teixeira De Castro, Xavier, & Nobrega, 2009), and cardiac 
remodeling (Li et al., 2004), normal cardiovascular function can be restored, or at least 
improved, following AChE inhibition or treatment with chronic vagal stimulation (Lara 
et al., 2010; Li et al., 2004). 
Both animal studies, as well as human studies, have shown that AChE inhibition can be 
beneficial in restoring normal cardiovascular function in models with cardiac 
dysfunction.  For instance, those mice experiencing a reduction in the level of functioning 
VAChT protein (VAChT KDHOM) to approximately 30% of normal levels, presented with 
decreased levels of peak calcium, as well as a decrease in the rate of calcium decay (Lara 
et al., 2010). Inefficient calcium handling by cardiomyocytes has been shown to have a 
significant influence on the normal physiology of these cells (Bers, 2002, 2006). 
Furthermore, altered   calcium handling is considered to be a key biological marker for 
chronic heart failure (CHF) and several cardiac pathologies (Vahl, Bonz, Timek, & Hagl, 
1994). In addition to altered calcium handling, VAChT KDHOM mice exhibited significant 
reductions in left ventricular fractional shortening, indicative of left ventricular 
dysfunction (Lara et al., 2010). Interestingly, peak calcium and calcium decay, as well as 
left ventricular fractional shortening, were all restored to WT levels following AChE 
inhibition by PYR (Lara et al., 2010). These results suggest that cholinergic 
neurotransmission is critical for maintaining normal cardiovascular function, since a 
decrease in the level of functioning VAChT protein produced a phenotype consistent with 
heart dysfunction which was restored following AChE inhibition. The beneficial effects 
of AChE inhibition on cardiovascular function were also shown in a study by Okazaki et 
al., 2010 in which rats with CHF were treated with the AChEI donepezil. When these rats 
were subjected to AChE inhibition using donepezil, their left ventricular end diastolic 
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pressure (LVEDP) and heart weights were significantly reduced compared to controls. 
Similarly, neurohumoral factors associated with the SNS, including NE and epinephrine, 
were significantly reduced following treatment with donepezil. (Okazaki, Zheng, Li, & 
Sugimachi, 2010). Interestingly, the beneficial effects of AChE inhibition have been 
described in clinical trials as well (Serra et al., 2009). One such trial showed that AChE 
inhibition by PYR in patients with CHF elicited an increase resting HR variability and 
decreased the incidence of ventricular arrhythmias, while also improving HR recovery 
following exercise (Serra et al., 2009). Furthermore, a recent study examining the 
correlation between AChE inhibition and myocardial infarctions (MI) revealed that the 
use of AChEI was correlated to a reduction in the risk of MI and mortality rate 
(Nordstrom, Religa, Wimo, Winblad, & Eriksdotter, 2013). Interestingly, Nordstrom et 
al., 2013 reported that this correlation was even stronger when increasing doses of the 
AChEI were utilized.  
Similar to the beneficial effects of AChE inhibition on cardiovascular function, studies 
involving chronic vagal stimulation have also shown to be quite beneficial. A study 
performed by Li et al., 2004 showed that when rats with CHF underwent chronic vagal 
stimulation, there was a significant decrease in both hemodynamic changes, as well as 
heart weights, compared to control rats. Li et al., 2004 also reported that when rats with 
CHF underwent chronic vagal stimulation, there was a marked improvement in long-term 
survival rate by preventing the progression of pumping failure and cardiac remodeling. A 
study performed by Sabbah and Cohen in 2005 in which canines were induced with a MI 
through the use of an intracoronary embolism, revealed that there was a significant 
improvement in left ventricular hemodynamics following chronic vagal stimulation 
compared to control canines. Sabbah and Cohen (2005) also showed that concomitant use 
of a β-blocker, along with chronic vagal stimulation, resulted in a significant increase in 
left ventricular ejection fraction (LVEF), as well as a significant decrease in left 
ventricular end systolic volume (LVESV) compared to canines treated simply with a β-
blocker (Sabbah HN & Cohen U, 2005). It has also been reported that there was a 
significant increase in proinflammatory cytokines in models of CHF, including tumor 
necrosis factor alpha and interleukin 6, both of which are highly correlated with 
morbidity and mortality (H. Wang et al., 2003). Interestingly, there is a reduction in those 
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proinflammatory cytokines aforementioned following chronic vagal stimulation (H. 
Wang et al., 2003).  Clinical trials performed on individuals whose LVEF was less than 
35% also reaped the beneficial effects of chronic vagal stimulation. In these patients, 
electrical pulsers were implanted in such a fashion to ensure that vagal stimulation 
occurred at specific intervals based on the patient’s prior health. Data acquired 3 months 
following implantation showed that chronic vagal stimulation significantly reduced basal 
HR and significantly improved the distance in which these patients could travel during a 
six minute walk test (De Ferrari, Sanzo, & Schwartz, 2009). Furthermore, data acquired 
one year post implantation revealed a significant increase in the patient’s LVEF (De 
Ferrari et al., 2009). Not only did these data show the beneficial effect of chronic vagal 
stimulation on cardiovascular function, but patient interviews following this treatment 
also revealed that there was a general improvement in their quality of life (De Ferrari et 
al., 2009). 
Although those studies mentioned above show how AChE inhibition and chronic vagal 
stimulation are beneficial in restoring or maintaining normal cardiovascular function, 
other studies have shown more generally just how important the PSNS and its associated 
proteins are in maintaining cardiovascular homeostasis. For instance, it has been shown 
that mAChR-2 knockout mice display impaired ventricular function, as well as an 
increased susceptibility to cardiac stress and cardiomyocyte remodeling (LaCroix, 
Freeling, Giles, Wess, & Li, 2008; Lara et al., 2010). Furthermore, a study performed by 
Nolan et al., 1992 revealed a significant correlation between the degree of 
parasympathetic impairment and the severity of left ventricular dysfunction. Finally, it 
has been shown in both animal models and humans with CHF, that there is cholinergic 
transdifferentiation of the cardiac SNS. Transdifferentiation of the cardiac SNS is the 
result of several factors being secreted from failing cardiomyocytes which switch neurons 
normally sympathetic in nature, to cholinergic neurons by altering the neurotransmitter 
that is released (Kanazawa et al., 2010).  Inhibiting this transdifferentiation resulted in 
increased mortality within these mice. 
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1.7 The Emergence of Non-Neuronal Cholinergic Systems 
If one considers that essentially all living cells, including epithelial cells, endothelial 
cells, immune cells, etc., have the ability to synthesize ACh, then the idea of ACh acting 
solely as a neurotransmitter must be revised (Wessler & Kirkpatrick, 2008). Evidence 
supporting the synthesis of ACh by multiple non-neuronal cell types has been confirmed 
through several experiments. Such experiments have revealed ChAT immunoreactivity 
and ChAT enzymatic activity, as well as the intracellular presence of ACh in non-
neuronal cells (Wessler & Kirkpatrick, 2008). Although ACh has been found in several 
non-neuronal sources, an argument suggesting that its presence in these sources is due to 
neuronal contamination could be made. However, based on several findings from the last 
few decades, the possibility of non-neuronal contamination by neuronal sources can be 
ruled out. Two such studies were performed on isolated epithelial cells, as well as 
immune cells, where the presence of both ChAT mRNA and ChAT protein were found 
intracellularly (Grando et al., 1993; Klapproth et al., 1997). Several other studies have 
provided evidence supporting the work completed by Grando et al., 1993 and Klapproth 
et al., 1997, where they were able to detect ChAT within non-neuronal cells by using 
antibodies targeted against it (Wessler & Kirkpatrick, 2008). Perhaps the most 
convincing finding comes from the human placenta and its ability to synthesize, store, 
and release ACh in the absence of cholinergic innervation (Wessler et al., 2001). Finally, 
studies performed by Kao et al., 1976 and Schlereth et al., 2006 have provided evidence 
refuting the argument that ACh present within non-neuronal sources was due to neuronal 
contamination. In these two studies, botulism toxin was used to inhibit the exocytotic 
release of ACh. When dermal microdialysis was utilized following this treatment, it was 
determined in vivo, that human skin cells could secrete non-neuronal ACh (Kao, 
Drachman, & Price, 1976; Schlereth et al., 2006). Considering the studies 
aforementioned, it becomes apparent that non-neuronal cells possess the ability to 
synthesize, store, and release ACh.  
Although several functions have been attributed to the non-neuronal release of ACh, 
perhaps its role in signal transduction is most important (Wessler & Kirkpatrick, 2008). 
As a signal transducing molecule, ACh can act through autocrine and paracrine 
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mechanisms to regulate basic cellular functions including cell proliferation, cell 
differentiation, and cell-cell contact (Wessler, Herschel, Bittinger, & Kirkpatrick, 2007). 
Its role in signal transduction has been revealed in several physiological systems, as well 
as pathological conditions, including the placenta (Wessler et al., 2007), the pancreas 
(Rodriguez-Diaz et al., 2011), the colon (Yajima, Inoue, Matsumoto, & Yajima, 2011), 
lymphocytes (Kawashima & Fujii, 2004), and a variety of different cancers (Wessler & 
Kirkpatrick, 2008; Yajima et al., 2011). In the placenta for example, non-neuronal ACh 
acts through nAChRs to regulate blood flow and fluid volume in placental vessels, the 
uptake of nutrients, and vascularization during placental development (Wessler et al., 
2007). In the pancreas, non-neuronal ACh released by the alpha cells serves as a feed-
forwarding signal to sensitize the beta cell response to increasing glucose concentrations, 
thereby limiting glucose fluctuations within the plasma (Rodriguez-Diaz et al., 2011). 
Furthermore, it has been suggested that the intracellular signaling pathways activated by 
ACh may promote long-term survival of beta cells through the use of tropic factors 
(Rodriguez-Diaz et al., 2011). In the colon, non-neuronal ACh released from colonocytes, 
in conjunction with propionate stimulation, serves as a signaling molecule which can act 
in a paracrine fashion through muscarinic receptors to regulate chloride secretion (Yajima 
et al., 2011). Chloride secretion in the colon is critical to maintaining normal 
physiological function as it plays an essential role in regulating mucosal hydration 
(Barrett & Keely, 2000). Finally, studies have revealed the synthesis and release of non-
neuronal ACh from tumor cells (Song & Spindel, 2008) and lymphocytes (Kawashima & 
Fujii, 2004). Tumor cells, such as those found in lung cancers, have revealed that non-
neuronal ACh can act in an autocrine or paracrine fashion to stimulate an increase in 
tumor cell growth (Song & Spindel, 2008).  Furthermore, it has been shown that 
lymphocytes possess an intrinsic non-neuronal cholinergic system as well (Kawashima & 
Fujii, 2004). This system has been shown to serve a role in the cholinergic anti-
inflammatory pathway by regulating immune function as well as local circulation 
(Kawashima & Fujii, 2004; Rosas-Ballina et al., 2011)   
Interestingly, recent evidence has revealed that the machinery required for the synthesis 
and release of ACh is present within cardiomyocytes themselves (Kakinuma, Akiyama, 
& Sato, 2009; Rana et al., 2010; Rocha-Resende et al., 2012). Results from these studies 
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have shown that the VAChT localizes in the perinuclear region of cardiomyocytes 
(Kakinuma et al., 2009; Rana et al., 2010; Rocha-Resende et al., 2012). Similarly, these 
studies have shown that ChAT localizes in and around the nucleus, while CHT1 localizes 
at the plasma membrane (Kakinuma et al., 2009; Rana et al., 2010; Rocha-Resende et al., 
2012). The presence of the VAChT, ChAT, and CHT1 and their locations throughout 
cardiomyocytes puts them in an ideal position to synthesize and secrete ACh.  Since it 
has been shown previously that cardiomyocytes can in fact secrete ACh (Kakinuma et al., 
2009; Rocha-Resende et al., 2012), it would be interesting to determine the mechanism 
by which cardiomyocytes are regulating this release. 
 
1.8 Direction, Aims, and Hypothesis 
As mentioned previously, ACh release at the heart is essential in maintaining 
cardiovascular function. More specifically, AChE inhibition, as well as chronic vagal 
stimulation, has been shown to improve left ventricular function in models of CHF. 
These findings are perplexing as parasympathetic innervation is found mainly at the 
SA/AV node and only sparsely at the ventricles. Based on the recent emergence of a non-
neuronal cholinergic system within cardiomyocytes, (Kakinuma et al., 2009; Rana et al., 
2010; Rocha-Resende et al., 2012) along with their ability to secrete ACh (Kakinuma et 
al., 2009; Rocha-Resende et al., 2012; A. Roy, Fields, W.C., Rocha-Resende, C., 
Resende, R.R., Guatimosim, S.,Prado, V.F.,Gros, R., and Prado, M.A. , 2013), these 
results taken together could suggest that this system serves a physiologically important 
role in the heart. To better understand how a non-neuronal cholinergic system functions 
in the heart, the aim of this project was to determine the mechanism regulating ACh 
release from cardiomyocytes. Considering ACh released from cholinergic neurons is 
regulated by the VAChT (de Castro et al., 2009; Lara et al., 2010), it is thought that ACh 
released from cardiomyocytes may be regulated in a similar fashion. Therefore, the 
hypothesis of this study is that ACh secreted from neonatal murine cardiomyocytes is 
regulated by the actions of the VAChT. To test this hypothesis, we will 
pharmacologically inhibit the VAChT in control mice using VES and we will also 
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analyze a genetically modified mouse line in which this transporter has been 
conditionally removed from cardiomyocytes.  
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Chapter 2 
2 Methods 
2.1 Animals 
Transgenic mice used for the present study were acquired from JAX Laboratories 
(B6.FVB-Tg(Myh6-cre)2182Mds/J, stock #011038). Expression of Cre in these mice was 
under the control of the cardiomyocyte-specific murine alpha myosin-heavy chain 
promoter (Myh-6-cre). Once acquired, transgenic mice were then bred to VAChT-floxed 
mice (VAChTflox/flox) (Guzman et al., 2011; Martins-Silva et al., 2011). All procedures 
and animals used in this thesis were approved by the local animal users committee 
(Protocol# 2008-127). As described previously, VAChTflox/flox mice were backcrossed 5 
times to C57BL6/j mice (Guzman et al., 2011). Furthermore, it should be noted that 
VAChTflox/flox mice were no different from wild-type mice (Martins-Silva et al., 2011). In 
order to generate VAChTflox/flox,Myh6-Cre+ and VAChTflox/flox,Myh6-Cre- mice, 
VAChTWT/flox,Myh6-Cre+ littermates were crossed with VAChTWT/flox,Myh6-Cre- littermates. 
Mice used for the present study were generated by breeding F2 littermates together. For 
the present study, VAChTflox/flox,Myh6-Cre- littermates were considered as controls. 
 
 
2.2 Neonatal Cardiomyocyte Cultures 
Neonatal cardiomyocytes were cultured as previously described (Guatimosim et al., 
2008) and used for all subsequent experiments. Neonatal cardiomyocytes were used over 
their adult counterparts as adult cardiomyocytes are only viable in culture for a short 
period of time consequently making them difficult to work with and obtain accurate 
results. In short, neonatal mice were sterilized, decapitated, and their hearts were 
extracted with any excess blood being removed by gently shaking the hearts in Hanks’ 
Balanced Salt Solution [(HBSS; Sigma Aldrich; 55021C) (5.37 mmol/L potassium 
chloride, 0.44 mmol/L potassium phosphate monobasic anhydrous, 4.17 mmol/L sodium 
bicarbonate, 136.89 mmol/L sodium chloride, 0.336 mmol/L sodium phosphate dibasic 
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heptahydrate, 5.55 mmol/L dextrose anhydrous, and 0.028 mmol/L phenol red sodium 
salt)]. Hearts were then cut, washed, and supplemented with 2 mL of Liberase solution 
[Liberase TH enzyme (Roche; 05401135001) stock solution reconstituted in 10 mL of 
HBSS] before being left in a water bath at 37oC with agitation for 10 minutes. The tissue 
was replaced with 4 mL of fresh Liberase solution and incubated at 37oC for 15 minutes. 
Cardiomyocytes were suspended in the Liberase solution and centrifuged at 200 x g for 5 
minutes at 23oC. The supernatant was discarded and the pellet was re-suspended in 3 mL 
of complete M199 medium (Sigma M4530) supplemented with 100 units/mL penicillin, 
100 μg/mL streptomycin, 10% Fetal Bovine Serum and 2 mmol/L L-glutamine. The 
process was repeated with the remaining undigested tissue before the cardiomyocytes 
were pre-plated in a petri dish (diameter x height: 100 mm x 25 mm) and incubated in a 
37oC incubator with 5% CO2 for 90 minutes. Following incubation, any tissue residue 
present at the surface of the medium was removed before the cardiomyocytes were re-
suspended. The resulting medium was centrifuged using the same parameters as 
previously described and the supernatant was discarded with the pellet being re-
suspended in complete M199 medium. In the case of assay-based studies, 
cardiomyocytes were re-suspended in enough medium such that each well of a 4 well 
plate contained 3 x 105 cells. In the case of microscopy-based studies, cardiomyocytes 
were re-suspended in enough medium such that each plate contained 1.5 x 105 cells. 
Cardiomyocytes used for assay-based studies were left to incubate overnight while 
cardiomyocytes used for microscopy-based studies were left in the incubator for 30 
minutes before additional medium was added. These plates were then placed in the 
incubator for overnight incubation. The following morning, cardiomyocytes were 
examined and the medium was changed to complete M199 medium supplemented with 
20 μg/mL of cytosine-D-arabinofuranoside (ARA-c) (Sigma Aldrich; C1768). Following 
incubation with ARA-c for 48 hours, the medium was changed to warmed M199 
medium. Cardiomyocytes were then used for their respective experiments (ie. 
Immunofluorescence/confocal microscopy, DAF-FM Diacetate Imaging, HPLC-ED, or 
the Choline/ACh Fluorometric Assay). Cardiomyocytes to be used for these experiments 
could be left in a 37oC incubator with 5% CO2 for up to one week from the initial culture 
day before they were no longer viable. 
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2.3 Genotyping 
Tail snips were taken from1-2 day old neonatal mice, placed in Eppendorf tubes, and 
supplemented with 25 µL of extraction solution (Sigma Aldrich; E7526) and 7 µL of 
tissue preparation solution (Sigma Aldrich; T3073). Eppendorf tubes were placed in a 
water bath at 37oC for 10 minutes with agitation and then placed onto a hot plate at 95oC 
for 5 minutes. Eppendorf tubes were supplemented with 25 µL of neutralization buffer 
(Sigma Aldrich; N9310) and vortexed before each neutralized solution was added to a 
PCR tube containing REDExtract-N-AMP PCR Reaction Mix (Sigma Aldrich; R4775) 
and primers (Flox GF, Flox GR, Cre-1, Cre-2, and VAT2DET2S). The positive control 
was supplemented with 1.5 µL of solution from a tube containing a tail snip of a Myh-6-
Cre Fx2 mouse. PCR tubes were then vortexed and spun down before being run on a PCR 
machine using a pre-made program. Upon completion of the program, each well of a 2% 
agarose gel was loaded with 7 µL of the resulting solution from its corresponding PCR 
tube. A 1 kb DNA ladder was also loaded for reference. The agarose gel was then run on 
a GE Gel Electrophoresis machine at 120 mv for 40 minutes and imaged. 
 
2.4 Cell Fixation and Immunofluorescence 
1-2 day old neonatal cardiomyocytes were cultured as previously described. Following a 
48 hour treatment with 20 μg/mL of ARA-c, medium present on cell culture plates was 
aspirated and cardiomyocytes were washed 3x using 1x Phosphate Buffer Solution 
(PBS). Cardiomyocytes were then covered with 4% paraformaldehyde (PFA), protected 
from light, and allowed to fix before being blocked with blocking solution (1x PBS + 
1%BSA + 0.5% Triton X-100). Cardiomyocytes were then incubated with anti-VAChT 
(Synaptic Systems) and α-Actinin (Sigma Aldrich) antibodies diluted 1:50 in blocking 
solution. Plates containing the anti-VAChT and α-Actinin antibodies were incubated 
overnight at 4oC. The following morning, cardiomyocytes were washed as previously 
described and incubated with secondary antibodies (Goat-α-Rabbit 488 and α-mouse 546) 
diluted 1:1000 in blocking solution. Each plate was left covered at room temperature for 
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1 hour before cardiomyocytes were subjected to nuclear staining using Hoescht 
Fluorescent Stain. Finally, cardiomyocytes were left in 2 mL of PBS, placed in a wet 
chamber, and left at 4oC until they were to be imaged. Imaging was completed using the 
63x objective lens of a Zeiss LSM 510 Meta confocal system. 
 
2.5 DAF-FM Fluorescence 
1-2 day old neonatal cardiomyocytes were cultured as previously described. Following a 
48 hour treatment with 20 μg/mL of ARA-c, the medium was removed, and 
cardiomyocytes were washed using 1mL of tyrode (140 mmol/L NaCl, 4 mmol/L KCL, 1 
mmol/L MgCl2, 1.8 mmol/L CaCl2, 10 mmol/L Glucose, and 5 mmol/L HEPES). Tyrode 
was then removed and replaced with 250 µL of DAF-FM (Invitrogen; D-23842) diluted 
in tyrode at a final concentration of 5 µM for 30 minutes. DAF-FM in tyrode was 
removed and cardiomyocytes were washed with 250 µL of fresh tyrode for 30 minutes. 
Cardiomyocytes were then either imaged (controls) or treated with various drugs 
including Pyridostigmine (100 µM) (Sigma Aldrich; P9797), Carbachol (10 µM) (Sigma 
Aldrich; C2409), Atropine (10 µM) (Sigma Aldrich; A0132), Hemicholinium-3 (10 µM) 
(Sigma Aldrich; H108) or Vesamicol (10 µM) (Sigma Aldrich; V100) for 30 minutes and 
then imaged. For the positive control, 1 nM sodium nitroprusside (SNP), a known nitric 
oxide (NO) donor, was added to a plate for approximately 1 minute and then imaged to 
determine if the assay was functioning properly. Images from each treatment were 
acquired using the 63x objective lens of a Leica SP5 II confocal system. Images were 
then analyzed using ImageJ software. 
 
2.6 Choline/ACh Fluorometric Assay 
Cardiomyocytes were cultured from VAChTflox/flox and VAChTMyh6-Cre-flox/flox neonatal 
mice as previously described. Following a 48 hour treatment with 20 μg/mL of ARA-c, 
VAChTflox/flox and VAChTMyh-6-Cre-flox/flox cardiomyocytes were treated with either 
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pyridostigmine (100 µM) or pyridostigmine and vesamicol (10 µM). The cultured 
medium was then collected, centrifuged at 13,200 RPM for 5 minutes at 4oC, and filtered 
using a 0.2 µM Acrodisc Syringe Filter (PALL Life Sciences; PN=4602). Known 
concentrations of ACh (0, 10, 20, 30, 40, and 50 pmol/well), as well as filtered cultured 
medium samples, were added to a 96-well plate and the volumes were adjusted to 50 
µL/well using choline assay buffer (Biovision; K615-100-1).  Next, two separate reaction 
mixes were created. The first reaction mix was created such that 50 µL of mix could be 
added to each well in the following proportions: 44 µL choline assay buffer, 2 µL choline 
probe (Biovision; K615-100-2A), 2 µL AChE (Biovision; K615-100-2), and 2 µL 
enzyme mix (Biovision; K615-100-4). The second reaction mix was created in a similar 
fashion with the exception of AChE. Instead, the second mix was created such that the 
AChE was replaced with an equivalent volume of choline assay buffer. Once the reaction 
mixes were added to their respective wells, the 96-well plate was removed from ice, 
covered with aluminum foil, and left at room temperature for 30 minutes.  The 96-well 
plate was then placed into a micro-plate reader with an Ex/Em=535/590 and a readout 
with given values was produced. The results were then normalized by subtracting the 
blank (ie. the 0 pmol/well standard) value from those values obtained for each well 
containing either a known standard or cultured medium. To determine the amount of ACh 
present within the cultured medium, the normalized values from wells lacking AChE (ie. 
free choline) were subtracted from the normalized values of wells containing AChE (ie. 
total choline). These values were then applied to a standard curve generated using known 
ACh standards.  
 
2.7 HPLC-Electrochemical Detection (HPLC-ED) 
Cardiomyocytes from VAChTflox/flox and VAChTMyh6-Cre-flox/flox neonatal mice were 
cultured as previously described. Following a 48 hour treatment with 20 μg/mL of ARA-
c, cardiomyocytes were treated with either pyridostigmine (100 µM) or pyridostigmine 
and vesamicol (10 µM) and left to incubate for 4 hours in a 37oC incubator with 5% CO2. 
Following incubation, the cultured medium was collected, centrifuged at 13,200 RPM for 
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5 minutes at 4oC, and filtered using a 0.2 µM Acrodisc Syringe Filter. The filtered 
cultured medium was loaded onto the autosampler of an UltiMATE 3000 HPLC system 
with a Coulochem electrochemical detector (ED). The cultured medium was then injected 
onto the UltiMATE 3000 system using the following components and parameters: Flow 
rate: 0.300 mL/min; Injection volume: 20 µL; Cell: Model 5040 amperometric cell with 
platinum target electrode (Thermo Scientific; 70-1074); Cell potential: 275 mV; Column: 
MGII CAPCELL PAK C18 column (Shiseido; Cat. No.= 92461); Column temperature: 
40oC; ACh post-column solid phase reactor (Thermo Scientific; 70-0640A) 
 
2.8 Statistical Analysis 
GraphPad Prism 6 was used for all statistical analysis in this study. The results for each 
of the experiments are provided as mean ± SEM. A student’s t-test or a one-way ANOVA 
with a Tukey’s post-hoc test were used to determine the statistical significance between 
experimental groups. p<0.05 was considered to be statistically significant for all analyses. 
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Chapter 3 
3 Results 
3.1 Neonatal Cardiomyocytes Secrete ACh in an Autocrine 
or Paracrine Fashion 
To determine if neonatal cardiomyocytes could secrete ACh, initially a DAF-FM 
bioassay was utilized. In this assay, secreted ACh elicits an increase in NO production 
and this production can be measured by DAF fluorescence. If neonatal cardiomyocytes 
could secrete ACh, it would be interesting to determine whether or not neonatal 
cardiomyocytes do so in an autocrine/paracrine fashion. Results obtained from the DAF-
FM bioassay would provide a foundation from which we could expand upon to better 
understand the way in which the non-neuronal cholinergic system functions in neonatal 
cardiomyocytes (Figure 1).  
Here we show that when VAChTflox/flox neonatal cardiomyocytes were subjected to AChE 
inhibition by PYR (100 µM), those cells exhibited a significant increase in DAF 
fluorescence similar to that observed in cardiomyocytes treated with exogenous Carb (10 
µM). The increase in DAF fluorescence following AChE inhibition signifies the 
preservation of ACh release by neonatal cardiomyocytes. The effects of PYR, as well as 
Carb, were blocked however, following pre-incubation with ATR (10 µM). To ensure the 
assay was functioning properly, VAChTflox/flox neonatal cardiomyocytes were treated with 
sodium nitroprusside (SNP), a known NO donor. Treatment with SNP resulted in a 
significant increase in DAF fluorescence compared to cardiomyocytes treated with 
exogenous Carb or PYR. 
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Figure 1. Acetylcholine release from cultured neonatal cardiomyocytes was 
determined using a DAF-FM bioassay following acute pharmacological treatments. 
(A) Representative images obtained using confocal microscopy depicting increased DAF 
fluorescence in VAChTflox/flox neonatal cardiomyocytes following acute treatment with 10 
µM exogenous carbachol (Carb) or 100 µM pyridostigmine (PYR) and no change in 
fluorescence when treated with 10 μM atropine (ATR), 10 μM ATR + 10 μM Carb, or 10 
μM ATR + 100 μM PYR. (B) Normalized DAF fluorescence in 1-2 day old 
VAChTflox/flox neonatal cardiomyocytes following acute treatment with exogenously 
added Carb, PYR, ATR or SNP. Number of cells subjected to each treatment are shown 
within their respective bars (n=). Cells were acquired from five separate neonatal 
cardiomyocyte cultures. Scale bar=20 μm. ***p<0.0001. Data are shown as mean ± 
SEM. 
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3.2 Pharmacological Inhibition of CHT1 by Hemicholinium-3 
Compromises ACh Release from Neonatal 
Cardiomyocytes 
The high affinity choline transporter, CHT1, has been shown to serve a critical role in 
regulating the re-uptake of choline into presynaptic cholinergic neurons (Ferguson et al., 
2004). This is evident considering that a disruption in the CHT1 gene results in impaired 
cholinergic neurotransmission (Ferguson et al., 2004). Interestingly, work by Rocha-
Resende et al., 2012 revealed the importance of CHT1 in the synthesis and subsequent 
release of ACh by adult cardiomyocytes, as pharmacological inhibition of this transporter 
by HEM severely compromised ACh release. Interestingly, Rana et al., 2010 were unable 
to locate CHT1, as well as other cholinergic proteins, within neonatal rat cardiomyocytes. 
Therefore, the purpose of this experiment was to determine, using DAF fluorescence, 
whether or not CHT1 regulates choline re-uptake and the subsequent release of ACh from 
neonatal murine cardiomyocytes (Figure 2). These data would not only provide evidence 
supporting ACh release by neonatal cardiomyocytes but they would inform us on whether 
or not a functional non-neuronal cholinergic system is present at birth and the possible 
physiological implications that this may have on cardiac development. Furthermore, they 
would provide greater insight into how a non-neuronal cholinergic system functions in 
cardiomyocytes.  
Following experimentation, we once again show that ACh release from VAChTflox/flox 
neonatal cardiomyocytes is preserved following AChE inhibition. Interestingly however, 
the effects of AChE inhibition were abolished when VAChTflox/flox neonatal 
cardiomyocytes were pre-incubated with HEM (10 µM). Treatment with SNP resulted in 
a significant increase in DAF fluorescence compared to those cardiomyocytes treated 
with exogenous Carb, PYR, or HEM + Carb signifying that the assay was functioning 
properly. 
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Figure 2. Acetylcholine release from cultured neonatal cardiomyocytes was 
determined using a DAF-FM bioassay following acute pharmacological treatments. 
 (A) Representative images obtained using confocal microscopy depicting increased 
DAF fluorescence in VAChTflox/flox neonatal cardiomyocytes following treatment with 
10 µM exogenous carbachol (Carb), 100 µM pyridostigmine (PYR), or 10 μM 
hemicholinium-3 (HEM) + 10 μM Carb and no change in fluorescence when treated 
with 10 μM HEM or 10 μM HEM + 100 μM PYR. (B) Normalized DAF fluorescence 
in 1-2 day old VAChTflox/flox neonatal cardiomyocytes following acute treatment with 
exogenously added Carb, PYR, HEM, or SNP. Number of cells subjected to each 
treatment are shown within their respective bars (n=). Cells were acquired from six 
separate neonatal cardiomyocyte cultures. Scale bar=20 μm. ***p<0.0001. Data are 
shown as mean ± SEM. 
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3.3 Pharmacological Inhibition of the Vesicular 
Acetylcholine Transporter by Vesamicol Compromises 
ACh Release from Neonatal Cardiomyocytes 
Previously, it has been shown that the VAChT serves a critical role in mediating the 
release of ACh from cholinergic neurons (de Castro et al., 2009), and it has yet to be fully 
determined if this transporter serves a similar role within neonatal cardiomyocytes. To 
elucidate whether or not the VAChT serves a similar physiological role in regulating the 
release of ACh from neonatal cardiomyocytes, the transporter was pharmacologically 
inhibited using vesamicol (VES) (Figure 3).  
Here we further confirm those observations previously reported (Rocha-Resende et al., 
2012) that the release of ACh by VAChTflox/flox neonatal cardiomyocytes is preserved 
following AChE inhibition.  When VAChTflox/flox neonatal cardiomyocytes were pre-
incubated with VES however, the release of ACh was inhibited despite the cells being 
subjected to AChE inhibition. Treatment with SNP resulted in a significant increase in 
DAF fluorescence compared to those cardiomyocytes treated with exogenous Carb, PYR, 
or VES+Carb signifying that the assay was functioning properly. 
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Figure 3. Acetylcholine release from cultured neonatal cardiomyocytes was 
determined using a DAF-FM bioassay following acute pharmacological treatments. 
 (A) Representative images obtained using confocal microscopy depicting increased DAF 
fluorescence in VAChTflox/flox neonatal cardiomyocytes following acute treatment with 10 
µM exogenous carbachol (Carb), 100 µM pyridostigmine (PYR), or 10 μM vesamicol 
(VES) + 10 μM Carb and no change in fluorescence when treated with 10 μM VES or 10 
μM VES + 100 μM PYR. (B) Normalized DAF fluorescence in 1-2 day old VAChTflox/flox 
neonatal cardiomyocytes following acute treatment with exogenously added Carb, PYR, 
VES, or SNP. Number of cells subjected to each treatment are shown within their 
respective bars (n=). Cells were acquired from six separate neonatal cardiomyocyte 
cultures. Scale bar=20 μm. ***p<0.0001. Data are shown as mean ± SEM. 
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3.4 The Conditional Removal of the Vesicular ACh 
Transporter from Neonatal Cardiomyocytes 
To further test for the role that the VAChT serves in mediating the release of ACh from 
neonatal cardiomyocytes, the transporter was conditionally removed from these cells. To 
differentiate VAChTflox/flox mice from VAChTMyh-6-Cre-flox/flox mice for subsequent 
experimentation, each mouse from a given litter was genotyped as previously described. 
Briefly, tail snips were taken from neonatal mice and subjected to PCR before the 
resulting DNA was run on a 2% agarose gel. For reference, a representative gel (Figure 
4) is shown to illustrate VAChTflox/flox and VAChTMyh-6-Cre-flox/flox genotyping. Each 
numbered lane represents a lane corresponding to a given mouse. Lanes labeled “P” and 
“N” are positive and negative controls, respectively. “L” represents a 1kb DNA ladder. 
VAChTflox/flox and VAChTMyh-6-Cre-flox/flox genotypes were determined by the presence of 
the flox/flox gene and either the absence or presence of Cre, respectively. In Figure 4, 
lanes 7, 10-12, and 14 denote mice of the VAChTflox/flox genotype, whereas the remaining 
lanes (1-6, 8, 9, and 13) denote mice of the VAChTMyh-6-Cre-flox/flox genotype. To confirm 
that the VAChT had been conditionally removed from VAChTMyh-6-Cre-flox/flox 
cardiomyocytes, immunostaining followed by confocal microscopy were performed on 
both VAChTflox/flox (Figure 5a) and VAChTMyh-6-Cre-flox/flox (Figure 5b) neonatal 
cardiomyocytes. Following the analysis of VAChTflox/flox neonatal cardiomyocytes, 
immunostaining and confocal microscopy revealed the presence of the VAChT within the 
perinuclear region. However, immunostaining and confocal microscopy in VAChTMyh-6-
Cre-flox/flox neonatal cardiomyocytes revealed no such VAChT staining within the 
perinuclear region. The lack of VAChT staining within these cardiomyocytes confirms 
the selective removal of the VAChT from neonatal cardiomyocytes.  
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Figure 4. Genotyping analysis of a cardiomyocyte specific VAChT KO mouse strain. 
An agarose gel used to distinguish VAChTflox/flox and VAChTMyh-6-Cre-flox/flox genotypes 
has been shown. Bands denoting Cre have been boxed in red while bands denoting flox 
have been boxed in yellow. Lanes 1-6, 8, 9, & 13 denote floxed Cre+ mice (VAChTMyh-6-
Cre-flox/flox), while lanes 7, 10-12, & 14 denote floxed Cre- mice (VAChTflox/flox). DNA 
obtained via tail snip from VAChTMyh-6-Cre-flox/flox mice was used as a positive control 
(Lane P) to show the presence of Cre. DNA obtained via tail snip from VAChTflox/flox 
mice was used as a negative control (Lane N) to show the absence of Cre. Lane L is a 1kb 
DNA ladder. 
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Figure 5. Conditional removal of the VAChT from cardiomyocytes in VAChTMyh-6-
Cre-flox/flox mice 
Representative images obtained by immunostaining and confocal microscopy showing 
the presence and absence of the VAChT within (A) VAChTflox/flox and (B) VAChTMyh-6-
Cre-flox/flox neonatal cardiomyocytes, respectively.  n=20 for both genotypes. Scale bar=20 
µm. 
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3.5 The Conditional Removal of the Vesicular ACh 
Transporter from Neonatal Cardiomyocytes Severely 
Compromises ACh Release 
Previous work has shown that the VAChT is essential in regulating the release of ACh 
from cholinergic neurons, as well as sustaining life, since deletion of this gene prevented 
the stimulated release of ACh from synaptosomes and resulted in death of the animals 
shortly after birth (de Castro et al., 2009). Furthermore, the essential role that the VAChT 
serves in mediating the release of ACh from cholinergic neurons has been shown in 
VAChT KDHOM mice. These mice exhibit alterations at the neuromuscular junction (de 
Castro et al., 2009) and display a myasthenic-like phenotype (V. F. Prado et al., 2006). 
To further determine if the VAChT serves a similar role within neonatal cardiomyocytes, 
we compared ACh release between VAChTflox/flox and VAChTMyh-6-Cre-flox/flox genotypes. 
Initially, VAChTflox/flox and VAChTMyh-6-Cre-flox/flox neonatal cardiomyocytes were 
subjected to analysis using the DAF-FM experimental approach as previously described 
(Figure 6). Here it was shown that the release of ACh by VAChTflox/flox neonatal 
cardiomyocytes was preserved following AChE inhibition, but no such preservation was 
observed in VAChTMyh-6-Cre-flox/flox neonatal cardiomyocytes subjected to the same 
treatment. 
To further test these findings, cultured medium was collected from VAChTflox/flox and 
VAChTMyh-6-Cre-flox/flox neonatal cardiomyocytes treated with either PYR (100 µM) or 
PYR + VES (10 µM) and subjected to analysis by a choline/ACh fluorometric assay 
(Figure 7). Both VAChTflox/flox and VAChTMyh-6-Cre-flox/flox neonatal cardiomyocytes were 
maintained in medium containing PYR to preserve ACh from degradation by AChEs. To 
determine the amount of ACh released under each of these conditions, standard curves 
were created separately for each assay using known ACh standards. One such standard 
curve has been shown for representative purposes (Figure 7c). Analysis revealed that 
VAChTflox/flox neonatal cardiomyocytes treated with VES released significantly less ACh 
compared to control cardiomyocytes incubated with only PYR (PYR: 199.2 ± 17.65 
pmols ACh/mg of protein, PYR+VES: 30.73 ± 3.89 pmols ACh/mg of protein, p<0.0001) 
(Figure 7a).  
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To further test these observations using genetic tools instead of pharmacology, 
VAChTflox/flox and VAChTMyh-6-Cre-flox/flox neonatal cardiomyocytes were treated with PYR 
(100 µM) before their cultured media were collected and subjected to fluorometric 
analysis (Figure 7b). Through the use of standard curves, it was determined that there 
was a significant reduction in ACh release from VAChTMyh-6-Cre-flox/flox neonatal 
cardiomyocytes compared to VAChTflox/flox neonatal cardiomyocytes (VAChTflox/flox: 
203.7 ± 23.95 pmols ACh/mg of protein, VAChTMyh-6-Cre-flox/flox: 1.67 ± 1.67 pmols 
ACh/mg of protein, p<0.001).  
To further confirm the lack of ACh release by VAChTMyh-6-Cre-flox/flox neonatal 
cardiomyocytes, cultured media were collected from VAChTflox/flox and VAChTMyh-6-Cre-
flox/flox neonatal cardiomyocytes which were treated with either PYR (100 µM) or PYR + 
VES (10 µM) and then subjected to analysis by HPLC-ED (Figure 8). To determine the 
amount of ACh released under each of these conditions, standard curves were created 
separately for each run using known ACh standards. One of these curves has been shown 
for representative purposes (Figure 8e). Representative chromatograms for VAChTflox/flox 
neonatal cardiomyocytes treated with either PYR or PYR + VES, along with a 500 fmol 
on the column (OTC) standard, have been shown for comparison (Figure 8c). Following 
the analysis of all runs from four separate neonatal cultures, the data revealed a 
significant reduction in ACh release from VAChTflox/flox neonatal cardiomyocytes treated 
with PYR+VES compared to  those cardiomyocytes treated with only PYR (PYR: 37.76 
± 4.51 pmols ACh/mg of protein, PYR+VES: 2.03 ± 1.17 pmols ACh/mg of protein, 
p<0.0001) (Figure 8a).  
To further compare VAChTflox/flox and VAChTMyh-6-Cre-flox/flox neonatal cardiomyocytes, 
they were treated with PYR (100 µM) and subjected to the same analysis. Representative 
chromatograms for VAChTflox/flox or VAChTMyh-6-Cre-flox/flox neonatal cardiomyocytes 
treated with PYR, along with a 250 fmol OTC standard, have been shown for comparison 
(Figure 8d). Analysis revealed a significant reduction in ACh release from VAChTMyh-6-
Cre-flox/flox neonatal cardiomyocytes compared to VAChTflox/flox neonatal cardiomyocytes 
(VAChTflox/flox: 47.89 ± 8.76 pmols ACh/mg of protein, VAChTMyh-6-Cre-flox/flox: 0.05 ± 
0.03 pmols ACh/mg of protein, p<0.01) (Figure 8b).  
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Figure 6. Acetylcholine release from cultured VAChTflox/flox and VAChTMyh-6-Cre-
flox/flox neonatal cardiomyocytes was determined using a DAF-FM bioassay following 
acute pharmacological treatments. 
 (A) Representative images obtained using confocal microscopy for VAChTflox/flox and 
VAChTMyh-6-Cre-flox/flox neonatal cardiomyocytes following acute treatment with either 10 
μM carbachol (Carb) or 100 μM pyridostigmine (PYR). Acute treatment with 10 μM 
Carb revealed a significant increase in DAF fluorescence in both VAChTflox/flox and 
VAChTMyh-6-Cre-flox/flox neonatal cardiomyocytes, whereas treatment with 100 μM PYR 
produced a significant increase in DAF fluorescence only in VAChTflox/flox neonatal 
cardiomyocytes B. Normalized fluorescence for 1-2 day old VAChTflox/flox and 
VAChTMyh-6-Cre-flox/flox neonatal cardiomyocytes following acute treatment with 
exogenously added Carb or PYR. Number of cells subjected to each treatment are shown 
within their respective bars (n=). Cells were acquired from six separate neonatal 
cardiomyocyte cultures. Scale bar=20 μm.*p<0.05. Data are shown as mean ± SEM. 
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Figure 7. Acetylcholine secreted by VAChTflox/flox and VAChTMyh-6-Cre-flox/flox 
neonatal cardiomyocytes was measured using using a choline/ACh Fluorometric 
Assay. 
 (A) Cultured VAChTflox/flox neonatal cardiomyocytes underwent acute treatment with 
either 100 μM pyridostigmine (PYR) or 100 μM PYR + 10 μM vesamicol (VES). 
Cultured media from a given treatment were separated from cells and the amount of 
secreted ACh was quantified. n=number of separate neonatal cardiomyocyte cultures for 
each treatment. ***p<0.0001 vs PYR. (B) Cultured VAChTflox/flox and VAChTMyh-6-Cre-
flox/flox neonatal cardiomyocytes underwent acute treatment with 100 μM PYR. Cultured 
media from a given genotype were separated from cells and the amount of secreted ACh 
was quantified. n=number of separate neonatal cardiomyocyte cultures for each genotype. 
**p<0.001 vs CT. (C) Representative standard curve used for the measurement of ACh 
created using a Choline/ACh fluorometric assay. 
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Figure 8. Acetylcholine secreted by VAChTflox/flox and VAChTMyh-6-Cre-flox/flox 
neonatal cardiomyocytes was measured using HPLC with electrochemical detection 
(ED). 
 (A) Cultured VAChTflox/flox neonatal cardiomyocytes underwent acute treatment with 
either 100 μM pyridostigmine (PYR) or 100 μM PYR + 10 μM vesamicol (VES). 
Cultured media from a given treatment were separated from cells and the amount of 
secreted ACh was quantified. n=number of separate neonatal cardiomyocyte cultures for 
each treatment. ***p<0.001 vs PYR (B) Cultured VAChTflox/flox and VAChTMyh-6-Cre-
flox/flox neonatal cardiomyocytes underwent acute treatment with 100 μM PYR. Cultured 
media from a given genotype were separated from cells and the amount of secreted ACh 
was quantified. n=number of separate neonatal cardiomyocyte cultures for each genotype. 
**p<0.01 vs VAChTflox/flox. (C) Representative chromatograms showing ACh release 
from VAChTflox/flox neonatal cardiomyocytes following treatment with either 100 μM 
PYR or 10 μM VES + 100 μM PYR, along with a blank and 250 fmol OTC standard for 
comparison. Numbers present above each peak represent retention times.  (D) 
Representative chromatograms showing ACh release from VAChTflox/flox and VAChTMyh-
6-Cre-flox/flox neonatal cardiomyocytes following treatment with 100 µM PYR, along with a 
blank and 500 fmol OTC standard for comparison. Numbers present above each peak 
represent retention times. (E) A representative standard curve ranging from 125-1000 
fmols OTC used to quantify ACh release. 
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Chapter 4 
4 Discussion 
4.1 Overview 
The recent emergence of non-neuronal cholinergic systems within biological systems 
such as the pancreas, the placenta, and the colon has provided insight and understanding 
into both the physiology, as well as the pathophysiology, associated with these systems. 
Recently, it has been reported that the heart possess an intrinsic non-neuronal cholinergic 
system, as the machinery required to synthesize and release ACh is present within 
cardiomyocytes themselves (Kakinuma et al., 2009; Rana et al., 2010; Rocha-Resende et 
al., 2012). However, there are controversial results regarding whether or not neonatal 
cardiomyocytes also possess this machinery as a recent report was unable to show the 
presence of cholinergic machinery in neonatal cardiomyocytes (Rana et al., 2010). In 
order to investigate the mechanisms involved in regulating ACh release from neonatal 
cardiomyocytes, a mouse line in which the VAChT has been conditionally removed has 
been generated. By utilizing a DAF-FM bioassay, a choline/ACh fluorometric assay, and 
HPLC-ED, we have shown pharmacologically, as well as genetically, that neonatal 
cardiomyocytes secrete ACh in a VAChT-dependent manner. The results obtained from 
neonatal cardiomyocytes agree with previous observations by Rocha-Resende et al., 2012 
that isolated adult cardiomyocytes can secrete ACh and can act in an autocrine/paracrine 
fashion through mAChRs-2. Furthermore, our results provide support for the role of 
CHT1 in the synthesis and subsequent release of ACh from adult cardiomyocytes 
(Rocha-Resende et al., 2012). These results also indicate that the non-neuronal 
cholinergic system is not only present in adult cardiomyocytes, but that it’s also present 
during the maturation of cardiomyocytes as well.  The most important finding however, 
as previously mentioned, was determining how essential the role of the VAChT is in 
regulating ACh release from neonatal cardiomyocytes. 
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4.2 ACh Release from Cardiomyocytes can Act in an 
Autocrine or Paracrine Fashion to Further Stimulate the 
Production of ACh 
The DAF-FM bioassay works based on the principle that secreted ACh elicits an increase 
in NO production. This production can then be measured through the use of DAF 
fluorescence. A study analyzing the non-neuronal cholinergic machinery within isolated 
adult cardiomyocytes utilized the DAF-FM bioassay to show the secretion of ACh by 
these cells (Rocha-Resende et al., 2012). It was also reported that non-neuronal ACh 
secreted from isolated adult cardiomyocytes could act as a local signaling molecule 
through the activation of mAChRs-2 (Rocha-Resende et al., 2012). The secretion of non-
neuronal ACh by cardiomyocytes in an autocrine/paracrine fashion is of particular 
importance as it may serve to be cardioprotective in nature through the amplification of 
neuronally released ACh. By implementing a similar pharmacological approach on 
cultured VAChTflox/flox neonatal cardiomyocytes, in conjunction with the DAF-FM 
bioassay, we have been able to corroborate the findings by Rocha-Resende et al., 2012.  
Our findings reveal that the effects of preserved ACh release from VAChTflox/flox neonatal 
cardiomyocytes are blocked following treatment with ATR, a muscarinic receptor 
antagonist, suggesting that non-neuronal ACh secreted by these cells acts in an 
autocrine/paracrine fashion through mAChRs-2. Similar to those observations presented 
by Rocha-Resende et al., 2012, our data also provide support to those findings presented 
by Kakinuma et al., 2009. In this particular study, rat cardiomyocytes underwent 
pharmacological treatment with 1 mM Pilocarpine, a non-selective muscarinic agonist, 1 
μM of the cholinesterase inhibitor Donepezil, or 1 mM ATR. Following treatment with 1 
mM Pilocarpine or 1 μM Donepezil, Kakinuma and colleagues observed a significant 
increase in intracellular ACh content (Kakinuma et al., 2009). Conversely, pre-incubation 
with 1 mM ATR prevented any significant increase in intracellular ACh and in fact,  
produced a significant reduction in intracellular ACh (Kakinuma et al., 2009). These 
observations suggest that ACh is synthesized and secreted constitutively by rat 
cardiomyocytes and acts through mAChRs-2 to actuate ACh production. The amount of 
ACh present within rat cardiomyocytes either increases or decreases from basal levels 
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following mAChR-2 activation or inhibition, respectively. These findings suggest that 
ACh produced by rat cardiomyocytes for subsequent release is in some way mediated by 
the mAChR-2. Although not fully known, our findings could suggest a similar regulatory 
role for the mAChR-2 in murine cardiomyocytes as well.  
The ability for non-neuronal ACh to act in an autocrine/paracrine fashion through 
muscarinic receptors is essential in maintaining normal physiology within several 
biological systems such as the pancreas (Rodriguez-Diaz et al., 2011). In the pancreas for 
instance, non-neuronal ACh secreted locally by the pancreatic alpha cells activates 
muscarinic type-3 ACh receptors (mAChR-3) to maintain glucose homeostasis, as well as 
proper insulin secretion. When the mAChR-3 is inhibited by J-104129, large fluctuations 
in plasma glucose concentrations ensue as a consequence of consistently reduced insulin 
responses (Rodriguez-Diaz et al., 2011).  
In fact, the importance of non-neuronal ACh acting in an autocrine/paracrine fashion 
through muscarinic receptors has been shown recently in the cardiovascular system as 
well.  It was reported that effectively abolishing the release of cardiomyocyte-derived 
ACh from murine cardiomyocytes through either pharmacological or genetic means, 
results in cardiomyocyte hypertrophy and cardiomyocyte remodeling (A. Roy et al., 
2013). Moreover, when subjected to stress, these mice presented with altered cardiac 
contractility, as well as left ventricular function (A. Roy et al., 2013). These observations 
suggest that the release of cardiomyocyte-derived ACh and its ability to activate 
mAChRs-2 in an autocrine/paracrine fashion, is essential in maintaining cardiovascular 
homeostasis since inhibiting this release through either pharmacological or genetic means 
produces severe alterations in cardiomyocyte structure and function. 
 Taken together it becomes clear that several cells types, despite being non-neuronal in 
nature, can secrete ACh and do so in an autocrine/paracrine fashion through mAChR. 
More importantly, these data show that murine cardiomyocytes can secrete ACh in a 
similar fashion and can activate mAChRs-2 to ensure cardiovascular homeostasis, by 
maintaining cardiomyocyte structure and function.  
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4.3 ACh Release from Cardiomyocytes is Compromised 
Following Inhibition of CHT1 by Hemicholinium-3 
As reported previously, the high affinity choline transporter, CHT1, is a protein essential 
to cholinergic neurotransmission, as it mediates the synthesis of ACh by providing 
cholinergic neurons with choline (Collier & Katz, 1974; R. Birks, 1961). This is evident 
considering that mutant mice possessing a disruption in the CHT1 gene produced 
alterations at the neuromuscular junction (Ferguson et al., 2004). Interestingly, these 
alterations paralleled those exhibited by ChAT mutant mice incapable of synthesizing 
ACh (Brandon et al., 2003; Misgeld et al., 2002) or VAChT mutants (de Castro et al., 
2009), suggesting that when CHT1 activity is compromised, the production and release of 
ACh are also compromised. In the present study, CHT1 was pharmacologically inhibited 
in cultured VAChTflox/flox neonatal cardiomyocytes using HEM. By pharmacologically 
inhibiting this transporter, we could determine if CHT1 regulates choline re-uptake in 
neonatal cardiomyocytes in a similar manner to neuronally-derived CHT1. Furthermore, 
by pharmacologically inhibiting CHT1 in neonatal cardiomyocytes, we could determine 
whether or not a non-neuronal cholinergic system is present and active during 
development.  
 These data show that ACh secreted by VAChTflox/flox neonatal cardiomyocytes is 
abolished, despite AChE inhibition, following pre-incubation with HEM. These data 
provide support to those observations reported by Rocha-Resende et al., 2012 where they 
pharmacologically inhibited CHT1 in isolated adult cardiomyocytes. Similar to the 
observations we report, Rocha-Resende et al., 2012 reported that ACh secreted from 
isolated adult cardiomyocytes was abolished following pre-incubation with HEM.  
Considering both VAChTflox/flox neonatal cardiomyocytes and isolated adult 
cardiomyocytes are able to preserve ACh release following AChE inhibition, but fail to 
do so following pre-incubation with HEM, suggests that the synthesis and subsequent 
release of ACh by murine cardiomyocytes is highly dependent upon CHT1 activity and 
its ability to regulate choline re-uptake. These data are important as they suggest that the 
role of CHT1 in cardiomyocytes is similar to its role in cholinergic neurons.  Taken 
together, it becomes clearly evident that CHT1 is not only essential in regulating the re-
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uptake of choline in cholinergic neurons, but it also serves a critical role in maintaining 
cholinergic tone within non-neuronal cell types as well. 
The ability for CHT1 to regulate choline re-uptake not only in isolated adult 
cardiomyocytes, but in neonatal cardiomyocytes as well, suggests that an intrinsic non-
neuronal cholinergic system is active in cardiomyocytes during development. It is likely 
that a non-neuronal cholinergic system is present in neonatal murine cardiomyocytes 
where it serves, like adult cardiomyocytes (A. Roy et al., 2013), to prevent 
cardiomyocyte remodeling and cardiomyocyte hypertrophy, as well as the functional 
implications associated with these molecular changes.  
Not only do our data show the importance of CHT1 in regulating the re-uptake of choline 
by neonatal cardiomyocytes and the possible cardioprotective role it serves in the non-
neuronal cholinergic system of cardiomyocytes, but they also suggest that these cells 
require extracellular sources of choline to properly synthesize ACh. This becomes 
important from a cholinergic signaling perspective as it has been previously reported that 
the de novo synthesis of ACh by cholinergic neurons is negligible and nearly all choline 
required for the synthesis of ACh must be acquired through dietary means (Fernstrom, 
1981; Zeisel, 1981).  
 
4.4 ACh Release from Cardiomyocytes is Regulated by the 
Vesicular ACh Transporter 
The role the VAChT serves within cholinergic neurotransmission has been well 
documented previously (Parsons et al., 1993; Usdin et al., 1995). The role it serves in 
packaging ACh into acidic vesicles is essential for sustaining life considering that 
VAChT KOHOM mice are not viable shortly after birth (de Castro et al., 2009).  In the 
present study, we both confirm and extend those data describing the role of the VAChT 
within cardiomyocytes by pharmacologically inhibiting the transporter, as well as 
conditionally removing it, from neonatal cardiomyocytes.  
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To more thoroughly understand the role this transporter serves in regulating ACh release 
from neonatal cardiomyocytes, multiple studies involving the pharmacological inhibition 
or conditional removal of the VAChT were performed. Experiments implementing the 
DAF-FM bioassay indicate that the release of ACh by VAChTflox/flox neonatal 
cardiomyocytes is compromised following treatment with VES. These findings are 
consistent with DAF-FM data acquired from isolated ventricular cardiomyocytes of mice 
with significant reductions in functioning VAChT protein (VAChT KDHOM), where it 
was reported that ACh release was severely compromised despite AChE inhibition 
(Rocha-Resende et al., 2012). Considering that AChEIs rely highly on preserved ACh 
release to properly exert their functions, the inability for PYR or NEO to mediate an 
increase in NO production (i.e. DAF fluorescence) when VAChT expression was 
reduced, or when the transporter was pharmacologically inhibited, indicates that the 
release of ACh was effectively abolished  This becomes even more evident considering 
that in both studies there was a significant increase in NO production when 
cardiomyocytes were treated with either exogenous Carb or ACh. Moreover, DAF-FM 
data acquired from VAChTMyh-6-Cre-flox/flox neonatal cardiomyocytes revealed no 
significant increase in NO production following AChE inhibition indicating that the 
VAChT is absolutely essential for the release of ACh by neonatal cardiomyocytes. These 
observations indicate that ACh released by cardiomyocytes is completed in a VAChT-
dependent manner similar to the manner in which ACh is released from cholinergic nerve 
terminals. This becomes evident considering that cardiomyocytes possess the recycling 
vesicles necessary for VAChT-dependent ACh release (Rocha-Resende et al., 2012). 
Interestingly, these vesicles have been shown to co-localize extensively with the VAChT 
in the perinuclear region of cardiomyocytes (Rocha-Resende et al., 2012).  
To further exam whether the release of ACh from cardiomyocytes occurs in a VAChT-
dependent manner, we utilized a choline/ACh fluorometric assay, as well as HPLC-ED, 
on both VAChTflox/flox and VAChTMyh-6-Cre-flox/flox neonatal cardiomyocytes. Both methods 
revealed results similar to those obtained following the pharmacological inhibition of the 
VAChT. These data not only support our previous findings, but they extend both our 
data, as well as the data of others, since until now no other study has shown through 
direct measurement, the secretion of ACh by cardiomyocytes. Even more convincing 
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however, is the fact that ACh release was almost completely undetectable by these 
methods when VAChTMyh-6-Cre-flox/flox neonatal cardiomyocytes were used. Considering 
that ACh secreted from cholinergic neurons in both the central and peripheral nervous 
systems is strongly correlated with the level of VAChT expression (V. F. Prado et al., 
2006), our data would seem to suggest that the level of VAChT expression within 
cardiomyocytes directly affects the amount of ACh released from these cells. Therefore, 
the release of ACh in a VAChT-dependent manner is not only a characteristic of 
cholinergic neurons, but also seems to be the manner in which ACh is secreted by 
cardiomyocytes. VAChT-dependent secretion of ACh by cardiomyocytes becomes even 
more plausible if one considers that other non-neuronal cholinergic systems have been 
shown to secrete ACh in this manner (Rodriguez-Diaz et al., 2011). In a study by 
Rodriguez-Diaz et al., 2011, AChE inhibition was ineffective in maintaining the 
pancreas’ insulin response when the VAChT was pharmacologically inhibited by VES.   
Taken together, both the pharmacological inhibition and conditional removal of the 
VAChT severely compromised the release of ACh from cardiomyocytes. Moreover, there 
were similar reductions in ACh release following both approaches. As it has been well 
established that the VAChT is essential in mediating the release of ACh from cholinergic 
neurons, results obtained following the pharmacological inhibition and conditional 
removal of it would suggest a similar VAChT-dependent release by neonatal 
cardiomyocytes. Determining the mechanism by which ACh is secreted by neonatal 
cardiomyocytes allows for a better understanding of the intrinsic non-neuronal 
cholinergic system within cardiomyocytes.  
 
4.5 Conclusions and Future Directions 
These data indicate that neonatal murine cardiomyocytes possess an intrinsic non-
neuronal cholinergic system that can synthesize and subsequently release ACh in an 
autocrine/paracrine fashion. Furthermore, pharmacologically inhibiting the VAChT or 
conditionally removing it from neonatal cardiomyocytes severely compromised ACh 
secretion suggesting that this process is VAChT-dependent. Although ACh release from 
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neonatal cardiomyocytes is VAChT-dependent, it is yet to be determined how this release 
changes under various physiological conditions such as acute and chronic stress. 
Determining how these conditions affect ACh release is not only critical to understanding 
cardiac physiology but it would also be critical to understanding the progression of 
several cardiac pathologies including CHF. Additionally, understanding how ACh release 
is altered under various physiological conditions may provide further insight into whether 
or not an intrinsic non-neuronal cholinergic system is cardioprotective in nature.  
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In the above publication, several contributions were made to see to its completion. My 
contributions to the paper involved both the direct, as well as the indirect measurements 
of ACh. More specifically, I was responsible for determining the amount of ACh released 
from both VAChTflox/flox and VAChTMyh-6-Cre-flox/flox neonatal cardiomyocytes under 
various pharmacological treatments using HPLC-ED and a choline/ACh fluorometric 
assay. Additionally, I was responsible for all the data acquired from VAChTflox/flox and 
VAChTMyh-6-Cre-flox/flox neonatal cardiomyocytes subjected to DAF-FM analysis. 
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